Audit: QRS - Adenosine for Hair Regrowth
Audit conducted on 26/09/2026 15:32 using AI4L / Opus 5.5
Summary
| Items | Count |
|---|---|
| Total | 94 |
| Passed | 86 |
| Failed | 0 |
| N/A | 8 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | “theoretical caution”, “untested together” and “may appear” carried over from the ER |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | “Rogaine” and “Japanese Dermatological Association” appear in the ER for the same facts |
| 1.6 | The QRS does not introduce new attributions. | 🟢 |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Technical terms glossed (methylxanthines, trichoscopy, DHEA-S, lichen planopilaris) |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | |
| 2.9 | It DOES NOT address the reader directly | 🟢 | |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. | 🟢 | |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “oral” / “administered orally” not “taken by mouth” / “given by mouth”; “injection” not “shot”; “adverse event” not “bad reaction”). This holds on EVERY surface, including the QRS lede — the stricter plain-language bar (see 2.7) does not license lay phrasing for route of administration. Direct quotes from sources are exempt. | 🟢 |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: • Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment” • Gate headings: “Contraindications”, “Key Interactions” • Tier labels: “High”, “Medium”, “Low”, “Speculative” • Table column headers in Monitoring: “Marker”, “Target”, “Why” |
🟢 | |
| 3.2 | All <span data-qrs-var="NAME">...</span> from the [qrs_template] are present in the the QRS. |
🟢 | All 34 template variables present; marker_# and qualitative_item_# expanded to 6 and 5 instances |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” | 🟢 | Only empty ER tier is Risks High; hidden per 13.5 with an HTML comment quoting “No risk reaches High” |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | Protocol labels “Standard lotion regimen”, “Duration”, “Conventional-first approach” match ER bold labels |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | No emoji found in the file |
| 4.5 | The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. | 🟢 |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | duration “00:01” quoted because it contains a colon |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) | 🟢 | |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) | 🟢 | |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | |
| 5.11 | The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) | 🟢 | |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &) |
🟢 | |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &) |
🟢 | |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | 2026-0926-1455 → 09/26/2026 |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] opens by saying what the intervention is — its kind (e.g., dietary supplement, prescription medication, peptide, plant, procedure, practice) — and what it is used for, in plain language, before any verdict on the evidence | 🟢 | Opens with “a naturally occurring messenger molecule applied to the scalp as a lotion or shampoo, is used to encourage thicker hair growth” |
| 7.2 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section | 🟢 | |
| 7.3 | [at_a_glance] is no longer than 70 words | 🟢 | 70 words |
| 7.4 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | |
| 7.5 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | |
| 7.6 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | |
| 7.7 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section | 🟢 | |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | |
| 8.3 | Individual [stop_items] are formatted as <li></li> |
🟢 | |
| 8.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | ER uses no ranking notation in the contraindications |
| 8.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. | 🟢 | |
| 8.8 | If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. <!-- empty: ER names no population that should avoid the intervention --> |
N/A | Section is not empty |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section | 🟢 | |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications | 🟢 | |
| 9.3 | Individual [caution_items] are formatted as <li></li> |
🟢 | |
| 9.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | |
| 9.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | ER uses no ranking notation in the interactions |
| 9.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. | 🟢 | |
| 9.8 | If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. <!-- empty: ER names no interaction that changes how the intervention is used --> |
N/A | Section is not empty |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section | 🟢 | |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section | 🟢 | |
| 10.3 | If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | ER provides more than three actionable aspects |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. | 🟢 |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | Thicker hairs (High) and women’s results first, reduced shedding (Low) last |
| 11.3 | If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | ER provides three time-to-effect aspects |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel | N/A | ER provides time-to-effect information |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section | 🟢 | |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | |
| 12.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | |
| 12.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective <SPAN> is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. |
N/A | All four benefit tiers have items |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section | 🟢 | |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | |
| 13.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | |
| 13.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective <SPAN> is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. |
🟢 | risks_high span set to display: none with ER-basis comment |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section | 🟢 | |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed | 🟢 | All 6 ER biomarkers listed |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. | 🟢 |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section | 🟢 | |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed | 🟢 | All 5 ER qualitative markers listed |
Issues 26/09/2026 15:32
Pass rate 100.00%. No issues found.
Issues 26/09/2026 15:30
- 2.7 — Unexplained term alopecia areata: The Contraindications item at line 546 lists “alopecia areata” without a plain-language gloss, while the adjacent “lichen planopilaris” is explained; the ER supplies “autoimmune patchy loss” for it.
Fixes 26/09/2026 15:30
- 2.7 — Unexplained term alopecia areata: Added the ER-derived gloss to the Contraindications item, changing “(alopecia areata; lichen planopilaris, …)” to “(alopecia areata, an autoimmune patchy hair loss; lichen planopilaris, …)”.
Issues 26/09/2026 15:27
- 13.4 — Parenthetical retained in risk item: The Medium risk at line 578 reads “Scalp itch and folliculitis (inflamed hair follicles)”, keeping parenthetical content that the Risks section requires to be stripped.
Fixes 26/09/2026 15:27
- 13.4 — Parenthetical removed from risk: Changed the Medium risk from “Scalp itch and folliculitis (inflamed hair follicles)” to “Scalp itch and inflamed hair follicles”, matching the ER Conclusion’s plain wording without a parenthetical.
Issues 26/09/2026 15:25
- 9.2 — Light therapy interaction omitted: caution_items (QRS lines 555–561) list 7 of the 8 ER Key Interactions. “Low-level light therapy (red-light devices): No interaction known; potentially additive for density” (ER line 270) is missing, even though the similar additive-effect supplements item is included.
Fixes 26/09/2026 15:25
- 9.2 — Light therapy interaction added: Added “Low-level light therapy (red-light devices): no interaction known, potentially additive” as the final caution_items entry, matching ER line 270.
Issues 26/09/2026 15:22
- 2.7 — Unexplained specialist terms: “Androgen excess” in marker_5_why (line 652) and “lichen planopilaris” in stop_items (line 546) are not explained in plain language; the ER gloss “(an immune scarring hair loss)” (ER line 278) was dropped.
Fixes 26/09/2026 15:22
- 2.7 — Unexplained specialist terms: Changed marker_5_why from “Androgen excess” to “Male-hormone excess”, and restored the ER gloss in stop_items as “lichen planopilaris, an immune scarring hair loss”.
Issues 26/09/2026 15:19
- 2.7 — Unexplained term “folliculitis”: The Medium risk item at line 577 reads “Scalp itch and folliculitis” without a plain-language gloss, although the ER expands the term as “folliculitis (inflamed hair follicles)” (ER line 217).
Fixes 26/09/2026 15:19
- 2.7 — Unexplained term “folliculitis”: Changed the Medium risk item from “Scalp itch and folliculitis” to “Scalp itch and folliculitis (inflamed hair follicles)”, using the ER’s own gloss.
Issues 26/09/2026 15:17
- 1.1 — Protocol sub overgeneralizes trials: action_1_sub (line 450) says “the dose used in all lotion trials”, whereas the ER Therapeutic Protocol states “the dose used in all Japanese, Iranian and white-male trials”.
Fixes 26/09/2026 15:17
- 1.1 — Protocol sub trial wording: Changed action_1_sub from “the dose used in all lotion trials” to “the dose used in all Japanese, Iranian and white-male trials”, matching the ER Therapeutic Protocol.
Issues 26/09/2026 15:15
- 1.2 — Cautious phrasing dropped for minoxidil: The Key Interactions item “Topical minoxidil (Rogaine): monitor, potentially additive” (QRS line 557) omits the ER’s hedge “untested together” (ER line 265), keeping only the positive additive claim.
Fixes 26/09/2026 15:15
- 1.2 — Minoxidil hedge restored: Changed the Key Interactions item from “Topical minoxidil (Rogaine): monitor, potentially additive” to “Topical minoxidil (Rogaine): monitor, potentially additive, untested together”, matching the ER’s cautious phrasing.
Issues 26/09/2026 15:11
- 2.7 — Unexplained specialist terms: “trichoscopy” appears in the Monitoring marker name (line 657) and cadence (line 670) without the ER gloss “magnified scalp imaging”, and “Topical retinoids” (line 558) drops the ER gloss “vitamin A–derived skin drugs”.
Fixes 26/09/2026 15:11
- 2.7 — Specialist terms glossed: Changed marker_6_name from “Hair density and thick-hair share (trichoscopy)” to “(trichoscopy, magnified scalp imaging)”, and restored the ER gloss in caution_items: “Topical retinoids (vitamin A–derived skin drugs; tretinoin, adapalene): caution”.
Issues 26/09/2026 15:09
- 9.5 — Microneedling qualifier dropped: The Microneedling item (QRS line 561) omits the ER parenthetical “(fine-needle skin rolling)” (ER line 269) entirely, although parenthetical qualifiers may be shortened but never dropped.
Fixes 26/09/2026 15:09
- 9.5 — Microneedling qualifier restored: Changed the Key Interactions item from “Microneedling: caution” to “Microneedling (fine-needle skin rolling): caution”, restoring the ER parenthetical.
Issues 26/09/2026 15:06
- 2.7 — Unexplained jargon in interactions: Key Interactions item 1 (QRS line 555) uses the specialist term “Methylxanthines” and drops the ER’s plain-language gloss “caffeine-type stimulants” (ER line 263).
Fixes 26/09/2026 15:06
- 2.7 — Restored Methylxanthines plain gloss: Changed Key Interactions item 1 from “Methylxanthines (caffeine, theophylline, aminophylline)” to “Methylxanthines (caffeine-type stimulants; caffeine, theophylline, aminophylline)”, matching the ER wording.
Issues 26/09/2026 15:03
- 9.4 — Mitigation elaboration in interaction: The Microneedling item (line 561) appends “(gap of at least 24 hours after a session before application)”, a mitigation taken from the ER bullet body rather than an ER parenthetical qualifier; other interaction items correctly omit their mitigations.
Fixes 26/09/2026 15:03
- 9.4 — Mitigation elaboration removed: Changed the Microneedling interaction from “Microneedling: caution (gap of at least 24 hours after a session before application)” to “Microneedling: caution”, dropping the ER-body mitigation.
Issues 26/09/2026 15:00
- 2.7 — DHEA-S acronym unexplained: marker_5_name (line 646) shows “DHEA-S” with no plain-language gloss, unlike the glossed TSH and 25(OH)D markers; the ER describes it as an adrenal male-type hormone.
- 9.5 — Minoxidil brand parenthetical dropped: The ER bullet “Topical minoxidil (Rogaine)” names an example product in parentheses, but the QRS item at line 557 drops it entirely.
Fixes 26/09/2026 15:00
- 2.7 — DHEA-S acronym glossed: Changed marker_5_name from “Total and free testosterone, DHEA-S (women)” to “Total and free testosterone, DHEA-S (adrenal male-type hormone), women”, using the ER’s own description.
- 9.5 — Minoxidil brand restored: Changed “Topical minoxidil: monitor, potentially additive” to “Topical minoxidil (Rogaine): monitor, potentially additive”, preserving the ER parenthetical.
Issues 26/09/2026 14:58
- 1.1 / 1.3 / 7.4 — At-A-Glance drops folliculitis: Line 433 states “Side effects appear limited to occasional scalp itch”, while the ER Conclusion says “occasional scalp itch or inflamed follicles”; the narrowed claim is unsupported and softens the ER’s risk statement.
Fixes 26/09/2026 14:58
- 1.1 / 1.3 / 7.4 — At-A-Glance folliculitis restored: Changed “Side effects appear limited to occasional scalp itch” to “…occasional scalp itch or inflamed follicles” to match the ER Conclusion; shortened “gains in hair count” to “hair-count gains” to stay within 70 words.